

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsang et al.

Serial No.: 09/633,034

Examiner: Huff, Sheela Jitendra

Filed : August 4, 2000

Group Art Unit: 1643

For : MONOCLONAL ANTIBODIES AGAINST HUMAN COLON  
CARCINOMA-ASSOCIATED ANTIGENS AND USES THEREFOR


**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States  
Postal Service as first class mail, in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

May 9, 2006  
Date of Deposit

Lisa B. Kole  
Attorney Name

  
Signature

35,225  
PTO Registration No.

May 9, 2006  
Date of Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed below and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of all U.S. Patents and Applications are not enclosed pursuant to the waiver of 37 CFR 1.98 (a)(2)(i) for all applications filed after June 30, 2003. Copies of all other listed documents are attached. References are numbered from 55-63 in continuation with references filed on November 16, 2005 in a prior supplemental Information Disclosure Statement. References marked with a “ § ” were cited in the

International Search Report in PCT/US95/11554 and those marked with an asterisk (\*) were cited in European Application No. EP 95933081, both of which are related to the present reissue Application and copies of which are enclosed.

55. Nakao et al., 1997 Am J Gastroenterol. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. 92(6):1031-4.
56. \*Wolf et al., 1993, J. Immunol. 150(8):p142A; Abstract No. 806 Immunohistological and Flowcytometry studies using monoclonal antibody.
57. §Wolf et al., 1993, Immunoreactivity of cell lines and colon carcinomas with monoclonal antibodies PCA 31.1 and PCA 33.28. Mol. Biol. Cell 4 (supp): p334A; Abstract 1940.
58. §Wolf et al., 1993, Monoclonal antibody 31.1 may differentiate indolent from aggressive colon cancer. Proc. Am. Assoc. Cancer Res. 34: p452 ; Abstract 2695.
59. §Hurwitz et al., 1992, Immunotargeting of Daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. Cancer Immunol. Immunother. 35:186-192.
60. §Kuroki et al., 1992, Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analysed with purified preparations of CEA and related normal antigens. Clin. Biochem. 25:29-35.
61. §Bartal et al., 1990, Monoclonal antibody defining an antigen present within a purified tumor membrane vaccine Proc. American Assoc. Cancer Res. 31: p260, Abstract No. 1537.
62. \*Tsang, 1987, Monoclonal antibodies to human colon carcinoma-associated antigens FASEB 46(3):1058, Abstract No. 4322.
63. §Hughes et al., (1986) Antigen expression in normal and neoplastic colonic mucosa: three tissue-specific antigens using monoclonal antibodies to isolated colonic glands. Cancer Res. 46:2164-2171.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are

material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited document(s) do not constitute "prior art" under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. Duplicate copies of this sheet are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:

  
Lisa B. Kole

Patent Office Reg. No. 35,225

BAKER BOTTS L.L.P.

30 Rockefeller Plaza

New York, New York 10112-4498

Attorney for Applicant(s)

(212) 408-2500

<b>Form PTO-1449 U.S. Department of Commerce</b> <b>(REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1643
	Examiner Huff, Sheela Jitendra	



### U.S. PATENT DOCUMENTS

*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

### FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	55	Nakao et al., 1997 Am J Gastroenterol. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. 92(6):1031-4.
	56	Wolf et al., 1993, J. Immunol. 150(8):p142A; Abstract No. 806 Immunohistological and Flowcytometry studies using monoclonal antibody
	57	Wolf et al., 1993, Immunoreactivity of cell lines and colon carcinomas with monoclonal antibodies PCA 31.1 and PCA 33.28. Mol. Biol. Cell 4 (supp): p334A; Abstract 1940

546758

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1643
	Examiner Huff, Sheela Jitendra	

Exam Initial	N o.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	58	Wolf et al., 1993, Monoclonal antibody 31.1 may differentiate indolent from aggressive colon cancer. Proc. Am. Assoc. Cancer Res. 34: p452 ; Abstract 2695.
	59	Hurwitz et al., 1992, Immunotargeting of Daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. Cancer Immunol. Immunother. 35:186-192.
	60	Kuroki et al., 1992, Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analysed with purified preparations of CEA and related normal antigens. Clin. Biochem. 25:29-35
	61	Bartal et al., 1990, Monoclonal antibody defining an antigen present within a purified tumor membrane vaccine Proc. American Assoc. Cancer Res. 31: p260, Abstract No. 1537
	62	Tsang, 1987, Monoclonal antibodies to human colon carcinoma-associated antigens FASEB 46(3):1058, Abstract No. 4322.
	63	Hughes et al., (1986) Antigen expression in normal and neoplastic colonic mucosa: three tissue-specific antigens using monoclonal antibodies to isolated colonic glands. Cancer Res. 46:2164-2171 (§).

546758

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.